What Syschem does

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer (Scrip Code 531173, ISIN INE121D01036) headquartered in Chandigarh with manufacturing operations in Panchkula, Haryana. The company produces Active Pharmaceutical Ingredients (APIs) and intermediates — including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium — alongside specialty chemicals and a broad portfolio of finished generic formulations spanning tablets, softgel capsules, injections, syrups/suspensions, and herbal/personal care products across antibiotics, anti-ulcerants, analgesics, neuroprotective agents, hormonal therapies, and nutritional supplements. Manufacturing is GMP-certified (2023) with ISO quality management and supported by an in-house R&D centre equipped with pilot-scale production capabilities for developing non-infringing Drug Master File (DMF) processes.

The business operates on a B2B sales-led model with two principal revenue streams: API/intermediate/contract manufacturing sales to domestic and international pharmaceutical companies, and branded generic formulation sales to domestic healthcare providers. Distribution is conducted through a direct sales force with dedicated international business development personnel, including a Senior Manager-International Business (API) and a GM Business Development focused on import/export. The company's go-to-market relies on direct outreach, a corporate website with product catalogs, and an extensive investor relations portal reflecting its public-company status. Pricing is quote-based with no public disclosure, and specific revenue figures, customer concentration, and headcount data are not disclosed.

Syschem has raised equity capital through two preferential issues in 2022 and 2024 to fund expansion, and its regulatory posture — including GMP certification, an EC grant, and DMF filings — indicates pursuit of regulated international markets for API exports. Governance is via a standard public-company board with promoter-led management control (Managing Director Ranjan Jain since 2011, Whole-Time Director Suninder Veer Singh since 2016), independent directors, and a Company Secretary. Notable risks visible in public disclosures include a show cause notice, an order for recovery of money, and a Regulation 30 QP pharma case closure, which warrant diligence alongside the absence of disclosed revenue and customer concentration metrics.

Name

Syschem

Legal name

Syschem (India) Limited

Website

https://syschem.in

Company type

Public

Operating status

Operating

Headcount range

101–250 employees

Short description

Syschem (India) Limited is a BSE-listed pharmaceutical manufacturer producing APIs, intermediates, specialty chemicals, and over 100 generic formulations (tablets, capsules, injections, syrups) for domestic and international B2B pharmaceutical customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing (APIs and Generic Formulations)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Bulk drug manufacturing
• Pharmaceutical intermediates
• Generic formulations
• Contract manufacturing

Headquarters

HQ city

Chandigarh

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. API/Intermediates Manufacturing: Manufacturing and sale of Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium to pharmaceutical companies.
2. Generic Formulations: Production and sale of generic pharmaceutical formulations including Tablets, Softgel/Capsules, Injections, Syrups & Suspensions, and Herbal & Personal Care products.
3. Contract Manufacturing: Custom manufacturing services for pharmaceutical companies requiring specialized production capabilities.
4. Specialty Chemicals: Manufacturing of specialty chemicals for pharmaceutical and related industries.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Syschem (India) Limited manufactures and sells Active Pharmaceutical Ingredients (APIs) including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium. The company also produces specialty chemicals, pharmaceutical intermediates, and a broad range of generic finished dosage forms (tablets, capsules, softgels, injections, syrups, and herbal/personal care products) for domestic and international pharmaceutical buyers, and offers contract manufacturing services.

Product overview

Syschem (India) Limited is a pharmaceutical company engaged in the manufacture of Bulk Drugs/Intermediates/Specialty Chemicals and contract manufacturing. The company's product portfolio consists of: (1) API/Intermediates including Amoxycillin Tri Hydrate, Ampicillin Tri Hydrate, Cloxacillin Sodium, Dicloxacillin Sodium, and Flucloxacillin Sodium used as foundational ingredients for formulations; (2) Generic finished dosage forms including Tablets (antibiotics, analgesics, nutritional supplements), Softgels/Capsules (anti-ulcerants, neuroprotective agents, antibiotics, hormonal products), Injections (antibiotics, steroids, nutritional supplements, antimalarials), Syrups/Suspensions (cough syrups, digestive aids, nutritional supplements), and Herbal/Personal Care products. The products serve multiple therapeutic categories including antibiotics, anti-ulcerants, neuroprotective agents, hormonal therapies, nutritional supplements, respiratory treatments, and hepatoprotective formulations.

Differentiator

Problem solved

Functional benefit

Brands

• Cefo-Zone: Antibiotic injection product
• Chemcin 500
• Pantosys
• Sefxone
• Med-Vit
• Lyc-Sys
• Syszyme
• Sysclav
• SYSMOX
• OMESYS
• VANCOSYS
• MEROSYS

Products and services

• Amoxycillin Tri Hydrate API Active Pharmaceutical Ingredient used as a beta-lactam antibiotic in the manufacture of various formulations, sold to pharmaceutical companies.
• Ampicillin Tri Hydrate API Active Pharmaceutical Ingredient with antibiotic properties used as a foundational ingredient in pharmaceutical manufacturing.
• Cloxacillin Sodium API Beta-lactam antibiotic API used in the production of semi-synthetic penicillins for pharmaceutical manufacturers.
• Dicloxacillin Sodium API Penicillinase-resistant antibiotic API for manufacturing anti-infective medications.
• Flucloxacillin Sodium API Beta-lactamase resistant antibiotic API used in pharmaceutical formulations.
• Generic Tablets (Antibiotics, Analgesics, Nutritional) Broad portfolio of generic finished tablet dosage forms spanning antibiotics (SYSCLAV-625, AZICHEM 500, SYSFLOX-500), analgesics (SYSFEN-P, SYSFEN-SP), nutritional supplements (SYSFER-XT, CHEM-VIT), anti-ulcerants, anti-allergics (MONTE-LC), corticosteroids (DIZCORT 6), and anti-cold (SYSCOLD) preparations.
• Generic Softgel/Capsule Products Range of softgel capsules and capsules including anti-ulcerants (PANTOSYS-DSR, RABEZOLE-DSR, OMESYS, OMESYS-DSR), neuroprotective agents (SYSBAL PLUS, SYSBAL PG), antibiotics (SYSMOX 250/500/DC), anti-fungals (ITROSYS 100/200), hormonal supplements (PREGACARE 100/200), and nutraceutical softgels (GLUTASYS, SHAKTI 40, SYSCAL-CT, OMEGASYS-G3, SYSCAL-60K, VEE SAFE).
• Generic Injection Products Sterile injectable pharmaceutical products including antibiotic injections (SEFXONE, CEFO-ZONE-S, SYSDIME, AZTREOSYS, SYSPIME, MEROSYS, VANCOSYS, SYPTAZ, IMILIFE-500, DORISYS, CHEMCIN), anti-analgesic injections (TRAMASYS, DICLOSYS-IV, PIROSYS-IV), hormonal injections (PREGASYS, PREGACARE INJ, ND 50, ND 25), corticosteroids (HYDROSYS), anti-ulcerant injections (PANTOSYS-IV, OMESYS-40 Inj, ESOMESYS-40 Inj), antimalarials (ARTESYS, RT-THER), neuroprotective and nutritional injections (CITISYS, MED-VIT INJ, SYSBAL-IV/FORTE), and supportive care injections (SYSRTON-INJ, TIGESYS-IV, CLINDASYS, SYSROSE-IV, COLISYS, SYSCLAV INJ).
• Generic Syrups and Suspensions Liquid oral pharmaceutical preparations including cough syrups (KUFKIL-LT, KUFKIL-DX), digestive syrups (SYSZYME), appetizer syrups (C-HEPRO T), multivitamin and mineral syrups (MED-VIT, CALCIWIN, LYCOSYS, SYSFER-XT suspension), and protein tonics (PRORICH-L).
• Herbal and Personal Care Products Herbal and personal care pharmaceutical products including uterine tonic (GYNESYS), hepatoprotective liver tonic (LIVOSYS-DS), and protein powder with DHA and minerals (PROWIN DHA).
• Contract Manufacturing Services Custom pharmaceutical manufacturing services for pharmaceutical companies requiring specialized production of bulk drugs and formulations at the company's GMP-certified facility in Panchkula.
• Specialty Chemicals Specialty chemicals manufactured for pharmaceutical and related industries, including intermediates used in the production of bulk drugs.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• Lupin: Indian pharma with significant cephalosporin and penicillin API manufacturing and US/EU DMF portfolio, closely mirroring Syschem's API focus and regulated-market strategy.
• Mankind Pharma: Dominant Indian branded-generics company with extensive anti-infective, gastro, and nutraceutical portfolio directly overlapping Syschem's formulation range, though at vastly larger scale and brand investment.
• Alkem Laboratories: Indian branded-generics and API manufacturer with strong domestic acute-care portfolio (anti-infectives, gastro) overlapping Syschem's therapeutic mix, but with a much larger field force and export footprint.
• Cipla: Major Indian pharma with broad API and formulation capabilities, including antibiotics and injectables, plus strong international/export presence — comparable product mix and regulatory ambitions.
• Aurobindo Pharma: Large Indian API and finished-formulation manufacturer with significant US/EU DMF presence and penicillin/cephalosporin API capabilities — directly comparable product overlap, but at materially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Syschem